Sodium-Glucose Linked Transporter-2 (SGLT-2) Inhibitor-Associated Unmasking of Myasthenia Gravis in a Patient With Undiagnosed Thymic Follicular Hyperplasia: The First Reported Case
Abstract
Myasthenia gravis is an autoimmune disease of the neuromuscular junction, primarily caused by antibodies directed against the acetylcholine receptor. Follicular hyperplasia of the thymus can be seen in patients with acetylcholine receptor-positive myasthenia gravis and may remain asymptomatic for many years until unmasked by a specific medication. Myasthenia gravis induced by drugs has been reported with D-penicillamine and immune checkpoint inhibitors, but never with the sodium-glucose linked transporter-2 inhibitors. We report a case of a 62-year-old man with type 2 diabetes presenting with progressive, fluctuating bilateral ptosis, binocular diplopia, dysarthria, and dysphagia occurring eight weeks after starting treatment with 10 mg daily of empagliflozin. He had no history of any other medications or infections. Physical examination revealed fluctuating bilateral ptosis (more prominent on the right) with an ice pack test demonstrating a 2 mm improvement after two minutes. The anti-acetylcholine receptor antibody level was positive at 4.2 nmol/L. Repetitive nerve stimulation studies revealed an 18% decremental response at 3 Hz. A chest computed tomography scan showed diffuse bilateral symmetric thymic hyperplasia measuring 12 mm in size without any mass. Empagliflozin was discontinued. Pyridostigmine and prednisone 40 mg daily were started, with full resolution of his symptoms. The patient shows no symptoms at one year on pyridostigmine alone. This case represents the…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.